• Je něco špatně v tomto záznamu ?

MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension

I. Stalmans, KS. Lim, F. Oddone, M. Fichtl, JI. Belda, A. Hommer, G. Laganovska, C. Schweitzer, B. Voykov, T. Zarnowski, G. Holló

. 2024 ; 262 (1) : 179-190. [pub] 20230824

Jazyk angličtina Země Německo

Typ dokumentu randomizované kontrolované studie, multicentrická studie, časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc24007838
E-zdroje Online Plný text

NLK ProQuest Central od 1997-10-01 do Před 1 rokem
Medline Complete (EBSCOhost) od 2009-07-01 do Před 1 rokem
Health & Medicine (ProQuest) od 1997-10-01 do Před 1 rokem

Odkazy

PubMed 37615697
DOI 10.1007/s00417-023-06192-0
Knihovny.cz E-zdroje

UNLABELLED: PURPOSE : To compare the efficacy and safety of the fixed-dose combination (FDC) of netarsudil 0.02%/latanoprost 0.005% ophthalmic solution (NET/LAT; Roclanda®) with bimatoprost 0.03%/timolol maleate 0.5% (BIM/TIM; Ganfort®) ophthalmic solution in the treatment of open-angle glaucoma (OAG) and ocular hypertension (OHT). METHODS: MERCURY-3 was a 6-month prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, non-inferiority study. Patients (≥ 18 years) with a diagnosis of OAG or OHT in both eyes that was insufficiently controlled with topical medication (IOP ≥ 17 mmHg in ≥ 1 eye and < 28 mmHg in both eyes) were included. Following washout, patients were randomized to once-daily NET/LAT or BIM/TIM for up to 6 months; efficacy was assessed at Week 2, Week 4, and Month 3; safety was evaluated for 6 months. Comparison of NET/LAT relative to BIM/TIM for mean IOP at 08:00, 10:00, and 16:00 h was assessed at Week 2, Week 6, and Month 3. Non-inferiority of NET/LAT to BIM/TIM was defined as a difference of ≤ 1.5 mmHg at all nine time points through Month 3 and ≤ 1.0 mmHg at five or more of nine time points through Month 3. RESULTS: Overall, 430 patients were randomized (NET/LAT, n = 218; BIM/TIM, n = 212), and all received at least one dose of study medication. Efficacy analyses were performed at Month 3 on 388 patients (NET/LAT, n = 184; BIM/TIM, n = 204). NET/LAT demonstrated non-inferiority to BIM/TIM, with a between-treatment difference in IOP of ≤ 1.5 mmHg achieved at all time points and ≤ 1.0 mmHg at the majority of time points (six of nine) through Month 3. Mean diurnal IOP during the study ranged from 15.4 to 15.6 mmHg and 15.2 to 15.6 mmHg in the NET/LAT and BIM/TIM groups respectively, with no between-group statistically significant difference. No significant differences were observed in key secondary endpoints. No serious, treatment-related adverse events (AEs) were observed, and AEs were typically mild/moderate in severity. The most common treatment-related AEs were conjunctival hyperemia (NET/LAT, 30.7%; BIM/TIM, 9.0%) and cornea verticillata (NET/LAT, 11.0%; BIM/TIM, 0%). CONCLUSIONS: Once-daily NET/LAT was non-inferior to BIM/TIM in IOP reduction in OAG and OHT, with AEs consistent with previous findings. NET/LAT offers a compelling alternative FDC treatment option for OAG and OHT.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24007838
003      
CZ-PrNML
005      
20240423160322.0
007      
ta
008      
240412s2024 gw f 000 0|eng||
009      
AR
024    7_
$a 10.1007/s00417-023-06192-0 $2 doi
035    __
$a (PubMed)37615697
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gw
100    1_
$a Stalmans, Ingeborg $u Department of Ophthalmology, University Hospitals UZ Leuven, Louvain, Belgium. ingeborg.stalmans@mac.com $u Research Group of Ophthalmology, Department of Neurosciences, Catholic University KU Leuven, Louvain, Belgium. ingeborg.stalmans@mac.com $1 https://orcid.org/0000000175074512
245    10
$a MERCURY-3: a randomized comparison of netarsudil/latanoprost and bimatoprost/timolol in open-angle glaucoma and ocular hypertension / $c I. Stalmans, KS. Lim, F. Oddone, M. Fichtl, JI. Belda, A. Hommer, G. Laganovska, C. Schweitzer, B. Voykov, T. Zarnowski, G. Holló
520    9_
$a UNLABELLED: PURPOSE : To compare the efficacy and safety of the fixed-dose combination (FDC) of netarsudil 0.02%/latanoprost 0.005% ophthalmic solution (NET/LAT; Roclanda®) with bimatoprost 0.03%/timolol maleate 0.5% (BIM/TIM; Ganfort®) ophthalmic solution in the treatment of open-angle glaucoma (OAG) and ocular hypertension (OHT). METHODS: MERCURY-3 was a 6-month prospective, double-masked, randomized, multicenter, active-controlled, parallel-group, non-inferiority study. Patients (≥ 18 years) with a diagnosis of OAG or OHT in both eyes that was insufficiently controlled with topical medication (IOP ≥ 17 mmHg in ≥ 1 eye and < 28 mmHg in both eyes) were included. Following washout, patients were randomized to once-daily NET/LAT or BIM/TIM for up to 6 months; efficacy was assessed at Week 2, Week 4, and Month 3; safety was evaluated for 6 months. Comparison of NET/LAT relative to BIM/TIM for mean IOP at 08:00, 10:00, and 16:00 h was assessed at Week 2, Week 6, and Month 3. Non-inferiority of NET/LAT to BIM/TIM was defined as a difference of ≤ 1.5 mmHg at all nine time points through Month 3 and ≤ 1.0 mmHg at five or more of nine time points through Month 3. RESULTS: Overall, 430 patients were randomized (NET/LAT, n = 218; BIM/TIM, n = 212), and all received at least one dose of study medication. Efficacy analyses were performed at Month 3 on 388 patients (NET/LAT, n = 184; BIM/TIM, n = 204). NET/LAT demonstrated non-inferiority to BIM/TIM, with a between-treatment difference in IOP of ≤ 1.5 mmHg achieved at all time points and ≤ 1.0 mmHg at the majority of time points (six of nine) through Month 3. Mean diurnal IOP during the study ranged from 15.4 to 15.6 mmHg and 15.2 to 15.6 mmHg in the NET/LAT and BIM/TIM groups respectively, with no between-group statistically significant difference. No significant differences were observed in key secondary endpoints. No serious, treatment-related adverse events (AEs) were observed, and AEs were typically mild/moderate in severity. The most common treatment-related AEs were conjunctival hyperemia (NET/LAT, 30.7%; BIM/TIM, 9.0%) and cornea verticillata (NET/LAT, 11.0%; BIM/TIM, 0%). CONCLUSIONS: Once-daily NET/LAT was non-inferior to BIM/TIM in IOP reduction in OAG and OHT, with AEs consistent with previous findings. NET/LAT offers a compelling alternative FDC treatment option for OAG and OHT.
650    _2
$a lidé $7 D006801
650    12
$a glaukom s otevřeným úhlem $x diagnóza $x farmakoterapie $7 D005902
650    _2
$a timolol $x škodlivé účinky $7 D013999
650    _2
$a bimatoprost $x terapeutické užití $7 D000069580
650    _2
$a latanoprost $x škodlivé účinky $7 D000077338
650    _2
$a prospektivní studie $7 D011446
650    _2
$a nitrooční tlak $7 D007429
650    _2
$a antihypertenziva $x škodlivé účinky $7 D000959
650    _2
$a tonometrie oční $7 D014065
650    12
$a oční hypertenze $x diagnóza $x farmakoterapie $7 D009798
650    _2
$a oční roztoky $7 D009883
650    _2
$a výsledek terapie $7 D016896
650    _2
$a dvojitá slepá metoda $7 D004311
650    12
$a benzoáty $7 D001565
650    _2
$a beta-alanin $x analogy a deriváty $7 D015091
655    _2
$a randomizované kontrolované studie $7 D016449
655    _2
$a multicentrická studie $7 D016448
655    _2
$a časopisecké články $7 D016428
700    1_
$a Lim, Kin Sheng $u KCL Frost Eye Research Department, St Thomas' Hospital, London, UK
700    1_
$a Oddone, Francesco $u IRCCS Fondazione Bietti, Rome, Italy
700    1_
$a Fichtl, Marek $u Department of Ophthalmology, First Faculty of Medicine, Charles University and General University Hospital in Prague, Prague, Czech Republic $u Department of Ophthalmology for Children and Adults, Second Faculty of Medicine, Charles University and University Hospital Motol in Prague, Prague, Czech Republic
700    1_
$a Belda, Jose I $u Department of Ophthalmology, Hospital Universitario de Torrevieja, Alicante, Spain $u Visionker Eye Clinic, Torrevieja, Spain
700    1_
$a Hommer, Anton $u Private Office for Ophthalmology and Optometry, Albertgasse 39/10, 1080, Vienna, Austria
700    1_
$a Laganovska, Guna $u Riga Stradins University, P.Stradins Clinical University Hospital, Riga, Latvia
700    1_
$a Schweitzer, Cédric $u CHU Bordeaux, Department of Ophthalmology, 33000, Bordeaux, France $u Univ. Bordeaux, Inserm, Bordeaux Population Health Research Center, Team LEHA, UMR 1219, 33000, Bordeaux, France
700    1_
$a Voykov, Bogomil $u Centre for Ophthalmology, University Hospital Tuebingen, Tuebingen, Germany
700    1_
$a Zarnowski, Tomasz $u Department of Diagnostics and Microsurgery of Glaucoma, Medical University, Lublin, Poland
700    1_
$a Holló, Gábor $u Tutkimusz Ltd, Solymár, Hungary $u Eye Center, Prima Medica Health Centers, Budapest, Hungary $1 https://orcid.org/0000000209044849
773    0_
$w MED00001940 $t Graefe's archive for clinical and experimental ophthalmology $x 1435-702X $g Roč. 262, č. 1 (2024), s. 179-190
856    41
$u https://pubmed.ncbi.nlm.nih.gov/37615697 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20240412 $b ABA008
991    __
$a 20240423160318 $b ABA008
999    __
$a ok $b bmc $g 2081691 $s 1217605
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 262 $c 1 $d 179-190 $e 20230824 $i 1435-702X $m Graefe's archive for clinical and experimental ophthalmology $n Graefes Arch Clin Exp Ophthalmol $x MED00001940
LZP    __
$a Pubmed-20240412

Najít záznam

Citační ukazatele

Možnosti archivace